Brief: Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting For PMX PMA
11/09/2026 12:25
BRIEF-Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting For PMX PMA Sept 11 (Reuters) - Spectral Medical Inc EDT.TO:
SPECTRAL MEDICAL PROVIDES UPDATE FOLLOWING IN-PERSON FDA 100-DAY MEETING FOR PMX PMA
SPECTRAL MEDICAL - FDA DOES NOT REQUEST ADDITIONAL CLINICAL TRIAL AFTER 100-DAY PMA REVIEW
SPECTRAL MEDICAL - GAINS CLARITY ON INFORMATION REQUIRED FOR PMA REVIEW
SPECTRAL MEDICAL - DOES NOT EXPECT MATERIAL CHANGE TO REGULATORY TIMELINE
Source text: ID:nGNX8qZ42c
Further company coverage: EDT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spectral Medical
See all newsBrief: Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting For PMX PMA
Canada's Spectral Medical Q2 revenue falls on lower reagent sales
Brief: Spectral Medical And Vantive Announce Topline 12 Month Follow-Up Results From Spectral’S Tigris Trial
Canada's Spectral Medical Q1 revenue rises 56%, net loss narrows
Spectral Medical Q3 revenue up 34%